NewsBenzingaBioCryst Pharma eleva su guía de ventas para el ejercicio 2026 de $690.000 millones-$715.000 millones a $715.000 millones-$730.000 millones frente a una estimación de $710.134 millones BioCryst Pharma eleva su guía de ventas para el ejercicio 2026 de $690.000 millones-$715.000 millones a $715.000 millones-$730.000 millones frente a una estimación de $710.134 millones Benzinga 2026.11.04 12:06 (GMT+0) Open on Benzinga Other news AECOM Hikes Dividend, Backlog Hits Record $28 Billion Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’ Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’ Nvidia Forms Board Panel for Export-Control Oversight Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free Amazon Cranks Up Its India Clean Energy Investment With Fresh $7 Billion Bet
Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’
Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’
Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free